Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Daxor Corporation (Nasdaq: DXR) said the USPTO issued U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor.” The patent covers systems for continuous, remote tracking of absolute blood volume after a baseline test by combining Daxor blood-volume algorithms with subsequent hematocrit monitoring, including non-invasive wearable optical sensors (e.g., PPG). Daxor said it targets conditions such as heart failure, syncope, anemia, and polycythemia.

Original reporting
Published Jun 2, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor — source image
Decision brief

The 30-second read

$DXRBullishMed
01

Why it matters

Issued patent can improve DXR’s defensibility and strengthen commercialization narratives for continuous monitoring in heart failure, syncope, anemia, and polycythemia—potentially supporting future partnerships and product expansion.

02

Market read

Company-specific IP milestone for DXR in remote blood volume monitoring; likely a sentiment-positive catalyst with incremental, not immediate, financial impact absent commercialization/regulatory details.

03

What to watch

Key gating items not addressed here include FDA labeling/clearance scope for the remote system, payer coverage/reimbursement, and whether the wearable sensor approach performs robustly across patient populations and device types.

Relevance 8/10Novelty 7/10Timing: today’s news flow on a newly issued USPTO patent

Background

DXR develops blood volume analysis (BVA) diagnostics and now claims a patent for remote monitoring that anchors continuous non-invasive measurements (e.g., PPG wearables) to a precise baseline.

Company-level read

Ticker impact

$DXRBullishMedium confidence
Context

Daxor (DXR) received a USPTO-issued patent for a remote blood volume monitor integrating wearable Hct sensing with its baseline algorithms.

Expected impact

Likely modest positive bias for DXR as investors price incremental product/market expansion optionality; magnitude depends on current valuation and follow-on regulatory/commercial milestones.

Evidence & confidence

The article is a concrete, company-specific catalyst (issued patent) but does not include revenue, trial outcomes, FDA actions, or near-term contract wins that would typically drive a large repricing.

Market effects

Supports the broader remote patient monitoring/diagnostics theme, potentially improving sentiment toward companies developing non-invasive monitoring and algorithm-driven clinical decision support.

Limited; company is US-based and the patent is US-specific, so impact is primarily on DXR rather than regional peers.

Moderate; while the patent is US-issued, the underlying wearable/remote monitoring approach aligns with global digital health adoption trends.

Counterpoint

A patent alone may not translate into near-term adoption; clinicians may still require validation, reimbursement clarity, and workflow integration before meaningful sales ramp.

Key entities

  • Daxor Corporation

    NASDAQ-listed diagnostics company receiving USPTO patent for a remote blood volume monitoring system.

  • USPTO

    US patent authority that issued the patent covering remote blood volume monitoring methods/systems.

Related articles

$DXRMedAI 8/10

Daxor presents clinical data on blood volume analysis technology

Daxor Corporation (DXR) presented clinical data at the Heart Failure Society of America 2026 Annual Scientific Meeting, showing its blood volume analysis (BVA) technology improved patient outcomes in heart failure studies. The BVA system, FDA-cleared with over 95% accuracy, identified fluid issues and guided treatment. The company has operated for 50 years and holds ISO certification.

$ACADMed

Acadia presents additional data on Alzheimer’s psychosis drug

Acadia Pharmaceuticals (NASDAQ:ACAD) presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis, showing consistent efficacy signals at the 60 mg dose. The drug previously missed its primary endpoint but achieved nominal significance on key secondary endpoints. The company continues Phase 3 trials and is also investigating the drug for Lewy body dementia psychosis.

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

$NSRXMed

Nasus Pharma presents phase 2 data on intranasal epinephrine

Nasus Pharma (NYSE:NSRX) presented Phase 2 study data for NS002, an intranasal epinephrine powder, showing faster therapeutic threshold reach than autoinjectors. No serious adverse events were reported. The company plans a pivotal study by late 2026, with results expected in Q1 2027. NS002 is being developed as a needle-free alternative for anaphylaxis treatment.